Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 1.00 |
| ▸ | LCK | P06239 | 3/20 | 1.00 |
| ▸ | KDR | P35968 | 8/20 | 0.73 |
| ▸ | RET | P07949 | 1/20 | 0.73 |
| ▸ | KIF5B | P33176 | 1/20 | 0.73 |
| ▸ | BRAF | P15056 | 5/20 | 0.65 |
| ▸ | RAF1 | P04049 | 4/20 | 0.61 |
| ▸ | CSF1R | P07333 | 1/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.61 |
| ▸ | FLT4 | P35916 | 1/20 | 0.61 |
| ▸ | FLT3 | P36888 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | GMNN | O75496 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31061055 | 1.00 | EGFR (1.00) | EGFRLCKKDRRETKIF5B | |
| SCHEMBL20229657 | 0.85 | KDR (0.74) | EGFRLCKKDRRETKIF5B | |
| SCHEMBL13680204 | 0.85 | KDR (0.73) | EGFRLCKKDRRETKIF5B | |
| SCHEMBL15463614 | 0.84 | KDR (0.73) | EGFRLCKKDRRETKIF5B | |
| SCHEMBL1012448 | 0.84 | KDR (0.73) | EGFRLCKKDRRETKIF5B | |
| SCHEMBL31060791 | 0.84 | KDR (1.00) | EGFRLCKKDRRETKIF5B | |
| SCHEMBL6181628 | 0.84 | EGFR (0.72) | EGFRLCKKDRRETKIF5B | |
| SCHEMBL15463602 | 0.83 | EGFR (0.71) | EGFRLCKKDRRETKIF5B | |
| SCHEMBL18158553 | 0.82 | KDR (0.70) | EGFRLCKKDRRETKIF5B | |
| SCHEMBL23457663 | 0.82 | LCK (0.74) | EGFRLCKKDRRETKIF5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0871448-B1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | AVENTIS PHARMA INC (US) | 2005-03-02 | — | — | EP | claimed |
| US-20040014774-A1 | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | AVENTIS PHARMACEUTICALS INC. | 2004-01-22 | — | — | US | claimed |
| US-RE37650-E1 | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | AVENTIS PHARMACETICAL PRODUCTS, INC. | 2002-04-09 | — | — | US | claimed |
| EP-0871448-A4 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | RHONE POULENC RORER PHARMA (US) | 1999-12-29 | — | — | EP | claimed |
| EP-0871448-A1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-10-21 | — | — | EP | claimed |
| US-5710158-A | INHIBITORS OF PROTEIN TYROSINE KINASE AND EPIDERMAL GROWTH FACTOR | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-01-20 | — | — | US | claimed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | claimed |
| WO-1995015758-A1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-06-15 | — | — | WO | claimed |
| EP-0871448-B1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | AVENTIS PHARMA INC (US) | 2005-03-02 | — | — | EP | disclosed |
| EP-1488792-A2 | Quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | Aventis Pharmaceuticals Products Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040014774-A1 | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | AVENTIS PHARMACEUTICALS INC. | 2004-01-22 | — | — | US | disclosed |
| US-6645969-B1 | Antiproliferative, anticarcinogenic, and antiinflammatory agents; treatment of leukemia, psoriasis, bone disorders, and atherosclerosis | AVENTIS PHARMACEUTICALS INC. | 2003-11-11 | — | — | US | disclosed |
| CN-1100540-C | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties | AVENTIS PHARMA INC (US) | 2003-02-05 | — | — | CN | disclosed |
| US-RE37650-E1 | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | AVENTIS PHARMACETICAL PRODUCTS, INC. | 2002-04-09 | — | — | US | disclosed |
| US-5714493-A | ANTIINFLAMMATORY AGENT | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| US-5710158-A | INHIBITORS OF PROTEIN TYROSINE KINASE AND EPIDERMAL GROWTH FACTOR | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-01-20 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1996039145-A1 | PROTEIN TYROSINE KINASE ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS HAVING SELECTIVE INHIBITION OF HER-2 AUTOPHOSPHORYLATION PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| WO-1995015758-A1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014774-A1 | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | CSF1R, CSF3R, FLT3 | EGFR 628/4885LCK 114/4885KDR 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.